234 related articles for article (PubMed ID: 36261264)
1. Effects of primary granulocyte-colony stimulating factor prophylaxis on neutropenic toxicity and chemotherapy dose delivery in Chinese patients with breast cancer who received adjuvant docetaxel plus cyclophosphamide chemotherapy: a retrospective cohort study.
Kwok CCH; Wong WH; Chan LL; Wong SPY; Wang F; Wong MCS; Tse SLA
Hong Kong Med J; 2022 Dec; 28(6):438-446. PubMed ID: 36261264
[TBL] [Abstract][Full Text] [Related]
2. Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy.
Chan A; Fu WH; Shih V; Coyuco JC; Tan SH; Ng R
Support Care Cancer; 2011 Apr; 19(4):497-504. PubMed ID: 20232087
[TBL] [Abstract][Full Text] [Related]
3. Underutilisation of prophylactic G-CSF in breast cancer patients receiving adjuvant docetaxel/cyclophosphamide chemotherapy.
Ku M; Je NK
J Chemother; 2022 Dec; 34(8):534-542. PubMed ID: 34870568
[TBL] [Abstract][Full Text] [Related]
4. Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
Skedgel C; Rayson D; Younis T
Support Care Cancer; 2016 Jan; 24(1):387-394. PubMed ID: 26081595
[TBL] [Abstract][Full Text] [Related]
5. Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer.
Kimura Y; Sasada S; Emi A; Masumoto N; Kadoya T; Okada M
Support Care Cancer; 2021 Jul; 29(7):3507-3512. PubMed ID: 33146835
[TBL] [Abstract][Full Text] [Related]
6. A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
Clemons M; Fergusson D; Joy AA; Thavorn K; Meza-Junco J; Hiller JP; Mackey J; Ng T; Zhu X; Ibrahim MFK; Sienkiewicz M; Saunders D; Vandermeer L; Pond G; Basulaiman B; Awan A; Pitre L; Nixon NA; Hutton B; Hilton JF;
Breast; 2021 Aug; 58():42-49. PubMed ID: 33901921
[TBL] [Abstract][Full Text] [Related]
7. Febrile neutropenia incidence and the variable toxicity profile between brand and generic docetaxel in the adjuvant treatment of breast cancer with docetaxel and cyclophosphamide regimen.
Tarcha FV; Baccarin ALC; Barros LADR; Alencar EBA; Del Giglio A; Cruz FJSM
Einstein (Sao Paulo); 2023; 21():eAO0486. PubMed ID: 38126660
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
[TBL] [Abstract][Full Text] [Related]
9. Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer.
Papakonstantinou A; Hedayati E; Hellström M; Johansson H; Gnant M; Steger G; Greil R; Untch M; Moebus V; Loibl S; Foukakis T; Bergh J; Matikas A
Acta Oncol; 2020 Jan; 59(1):75-81. PubMed ID: 31583943
[No Abstract] [Full Text] [Related]
10. The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer--further observations from the IMPACT solid study.
Mäenpää J; Varthalitis I; Erdkamp F; Trojan A; Krzemieniecki K; Lindman H; Bendall K; Vogl FD; Verma S
Breast; 2016 Feb; 25():27-33. PubMed ID: 26801413
[TBL] [Abstract][Full Text] [Related]
11. Impact of granulocyte-colony stimulating factor on docetaxel-induced febrile neutropenia in patients with breast cancer.
Zekri J; Nawaz A; Rasool H; Ahmad I; Abdel Rahman H; Dada R; Abdelghany EM; Farag K; Ibrahim RB; Deibas MY; Kamel MK; Allithy A
J Oncol Pharm Pract; 2022 Dec; 28(8):1681-1686. PubMed ID: 34342555
[TBL] [Abstract][Full Text] [Related]
12. Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment.
Assi H; Murray J; Boyle L; Rayson D
Support Care Cancer; 2014 Dec; 22(12):3227-34. PubMed ID: 24996828
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study.
Sakurada T; Bando S; Zamami Y; Takechi K; Chuma M; Goda M; Kirino Y; Nakamura T; Teraoka K; Morimoto M; Tangoku A; Ishizawa K
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1107-1114. PubMed ID: 31502114
[TBL] [Abstract][Full Text] [Related]
14. Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.
Griffiths RI; Barron RL; Gleeson ML; Danese MD; O'Hagan A; Chia VM; Legg JC; Lyman GH
Pharmacoeconomics; 2012 Feb; 30(2):103-18. PubMed ID: 21967155
[TBL] [Abstract][Full Text] [Related]
15. Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.
Cousin S; Le Rhun E; Mailliez A; Fournier C; Bonneterre J
Bull Cancer; 2012; 99(7-8):75-80. PubMed ID: 22713627
[TBL] [Abstract][Full Text] [Related]
16. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
[TBL] [Abstract][Full Text] [Related]
17. The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis.
Do T; Medhekar R; Bhat R; Chen H; Niravath P; Trivedi MV
Breast Cancer Res Treat; 2015 Oct; 153(3):591-7. PubMed ID: 26337685
[TBL] [Abstract][Full Text] [Related]
18. Suboptimal duration of granulocyte colony-stimulating factor use and chemotherapy-induced neutropenia in women diagnosed with breast cancer.
Lin WT; Wen YW; Chien CR; Gau CS; Chiang SC; Hsiao FY
Clin Ther; 2014 Sep; 36(9):1287-94. PubMed ID: 25130388
[TBL] [Abstract][Full Text] [Related]
19. Febrile neutropenia in FEC-D regimen for early stage breast cancer: is there a place for G-CSF primary prophylaxis?
Miguel I; Winckler P; Sousa M; Cardoso C; Moreira A; Brito M
Breast Dis; 2015; 35(3):167-71. PubMed ID: 26406541
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy-induced febrile neutropenia: primary G-CSF prophylaxis indicated during docetaxel cycles.
van Dooijeweert C; van der Wall E; Baas IO
Neth J Med; 2019 Dec; 77(9):310-316. PubMed ID: 31814585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]